'''Surinabant''' ('''SR147778''') is a [[cannabinoid receptor type 1]] [[Antagonist (pharmacology)|antagonist]] developed by [[Sanofi-Aventis]].<ref>{{cite journal | last1 = Rinaldi-Carmona | first1 = M | last2 = Barth | first2 = F | last3 = Congy | first3 = C | last4 = Martinez | first4 = S | last5 = Oustric | first5 = D | last6 = Pério | first6 = A | last7 = Poncelet | first7 = M | last8 = Maruani | first8 = J | last9 = Arnone | first9 = M | last10 = Finance | first10 = O | last11 = Soubrié | first11 = P | last12 = Le Fur | first12 = G | year = 2004 | title = SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization | url = | journal = Journal of Pharmacology and Experimental Therapeutics | volume = 310 | issue = 3| pages = 905–14 | doi = 10.1124/jpet.104.067884 | pmid = 15131245 }}</ref> It is being investigated as a potential treatment for [[nicotine]] [[Substance dependence|addiction]], to assist [[smoking cessation]]. It may also be developed as an [[anorectic]] drug to assist with weight loss, however there are already several CB<sub>1</sub> antagonists or [[inverse agonist]]s on the market or under development for this application,<ref>{{cite journal | last1 = Doggrell | first1 = SA | year = 2005 | title = Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant? | url = | journal = Expert Opinion on Investigational Drugs | volume = 14 | issue = 3| pages = 339–42 | doi = 10.1517/13543784.14.3.339 | pmid = 15833065 }}</ref> so surinabant is at present mainly being developed as an anti-smoking drug,<ref>{{cite journal | last1 = Lamota | first1 = L | last2 = Bermudez-Silva | first2 = FJ | last3 = Marco | first3 = EM | last4 = Llorente | first4 = R | last5 = Gallego | first5 = A | last6 = Rodríguez | first6 =  | last7 = de Fonseca | first7 = F | last8 = Viveros | first8 = MP | date = Jan 2008 | title = Effects of adolescent nicotine and SR 147778 (Surinabant) administration on food intake, somatic growth and metabolic parameters in rats | url = | journal = Neuropharmacology | volume = 54 | issue = 1| pages = 194–205 | doi = 10.1016/j.neuropharm.2007.07.004 | pmid = 17720206 }}</ref> with possible application in the treatment of other addictive disorders such as [[alcoholism]].<ref>{{cite journal | last1 = Gessa | first1 = GL | last2 = Serra | first2 = S | last3 = Vacca | first3 = G | last4 = Carai | first4 = MA | last5 = Colombo | first5 = G | year = 2005 | title = Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats | url = | journal = Alcohol and Alcoholism | volume = 40 | issue = 1| pages = 46–53 | doi = 10.1093/alcalc/agh114 | pmid = 15582988 }}</ref><ref>{{cite journal | last1 = Lallemand | first1 = F | last2 = De Witte | first2 = P | date = Jul 2006 | title = SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats | url = | journal = Alcohol | volume = 39 | issue = 3| pages = 125–34 | doi = 10.1016/j.alcohol.2006.08.001 | pmid = 17127132 }}</ref> Other potential applications such as treatment of [[ADHD]] have also been proposed.<ref>{{cite journal | last1 = Louis | first1 = C | last2 = Terranova | first2 = JP | last3 = Decobert | first3 = M | last4 = Bizot | first4 = JC | last5 = Francon | first5 = D | last6 = Alonso | first6 = R | last7 = Cohen | first7 = C | last8 = Griebel | first8 = G | year = 2005 | title = Surinabant, a new CB1 receptor antagonist, displays efficacy in animal models of attention deficit/hyperactivity disorder | url = | journal = Behavioural Pharmacology | volume = 16 | issue = | page = S42 | doi=10.1097/00008877-200509001-00133}}</ref>

 
A dose ranging study was done for smoking cessation<ref>{{Cite journal|url = |title = Efficacy of a dose range of surinabant, a cannabinoid receptor blocker, for smoking cessation: a randomized controlled clinical trial.|date = Jul 2012|journal = J Psychopharmacol|accessdate = |doi = 10.1177/0269881111431623|pmid = 22219220 |volume=26 |pages=1003–9 | last1 = Tonstad | first1 = S | last2 = Aubin | first2 = HJ}}</ref> in 2012; it did not improve success rate, but reduced weight gain.  Inhibition of THC  effects on heart rate was seen at 20&nbsp;mg and 60&nbsp;mg but not 5&nbsp;mg.<ref>{{Cite journal|title = Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.|date = Jul 2013|journal = Br J Clin Pharmacol.|doi = 10.1111/bcp.12071|pmid = 23278647 |volume=76 |pages=65–77 |pmc=3703229 | last1 = Klumpers | first1 = LE | last2 = Roy | first2 = C | last3 = Ferron | first3 = G | last4 = Turpault | first4 = S | last5 = Poitiers | first5 = F | last6 = Pinquier | first6 = JL | last7 = van Hasselt | first7 = JG | last8 = Zuurman | first8 = L | last9 = Erwich | first9 = FA | last10 = van Gerven | first10 = JM}}</ref>
